Tucidinostat

DRUG13 trials

Sponsors

Huyabio International LLC, Chipscreen Biosciences, Ltd., First Affiliated Hospital, Sun Yat-Sen University, Ou Bai, MD/PHD, Guangdong Women and Children Hospital

Conditions

Breast CancerColorectal CancerDiffuse Large B-cell LymphomaHR+/HER2- Breast CancerLymphoma, T-Cell, PeripheralMetastatic or unresectable melanomaNon Small Cell Lung CancerPeripheral T Cell Lymphoma

Phase 1

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

RecruitingNCT05559008

Ruijin HospitalPeripheral T Cell Lymphoma

Start: 2022-09-30End: 2026-01-26Target: 116Updated: 2022-11-09

Phase 2

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

CompletedNCT04465097

First Affiliated Hospital, Sun Yat-Sen UniversityBreast Cancer

Start: 2020-07-08End: 2023-10-01Updated: 2023-10-17

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

CompletedNCT04661943

Ou Bai, MD/PHDDiffuse Large B-cell Lymphoma

Start: 2017-06-01End: 2024-07-31Updated: 2026-03-24

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Guangdong Women and Children HospitalBreast Cancer

Start: 2021-11-01End: 2024-12-30Target: 73Updated: 2021-08-11

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

wang shusenTriple Negative Breast Cancer

Start: 2022-08-01End: 2024-12-01Target: 126Updated: 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

wang shusenBreast Cancer

Start: 2022-10-03End: 2025-04-01Target: 73Updated: 2022-11-04

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Active, not recruitingNCT05519865

Chipscreen Biosciences, Ltd.Non Small Cell Lung Cancer

Start: 2022-10-26End: 2024-10-31Updated: 2024-08-07

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Hunan Cancer HospitalHR+/HER2- Breast Cancer

Start: 2023-02-07End: 2025-12-01Target: 90Updated: 2023-02-21

Phase 3

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Active, not recruitingNCT04231448

Chipscreen Biosciences, Ltd.Diffuse Large B-cell Lymphoma

Start: 2020-05-21End: 2025-06-30Updated: 2024-12-05

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

RecruitingNCT06497985

Chipscreen Biosciences, Ltd.Colorectal Cancer

Start: 2024-12-06End: 2028-09-30Target: 430Updated: 2026-03-19

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors

Active, not recruitingCTIS2024-516914-39-00

Huyabio International LLCMetastatic or unresectable melanoma

Start: 2022-04-27Target: 185Updated: 2025-04-02

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

RecruitingNCT06947967

Chipscreen Biosciences, Ltd.Lymphoma, T-Cell, Peripheral

Start: 2025-08-12End: 2032-12-31Target: 224Updated: 2025-09-15

Unknown Phase

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Beijing 302 HospitalBreast Cancer

Start: 2019-07-10End: 2022-08-01Target: 50Updated: 2022-03-11

Related Papers

Chidamide: Exploration of maintenance therapy for patients with DLBCL with HBV infection.

2025-12-01

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood2025-11-03

Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Blood2024-11-051 citations

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.

Journal of Clinical Oncology2024-06-0512 citations

Abstract P5-09-05: A phase II, single-arm study of histone deacetylases inhibitor Tucidinostat and Exemestane as neoadjuvant therapy in patients with hormone receptor positive HER2 negative breast cancer (NeoTEE trial)

Cancer Research2023-03-012 citations

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Clinical Epigenetics2020-10-2345 citations